Oakridge Internatinal Ltd (AU:OAK)
ASX:OAK
Top Page
Oakridge Internatinal Ltd
(Sydney:OAK)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.06
▼(-22.50% Downside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak cash generation and ongoing losses, alongside a strong negative price trend and bearish momentum signals. A low P/E offers some valuation support but is not enough to offset the financial and technical weaknesses.
Positive Factors
Revenue Recovery
A pronounced top-line rebound in 2025 and >100% reported revenue growth indicate improving product uptake or contract wins. Durable revenue momentum helps absorb fixed costs, supports scaling, and creates a clearer path to sustainable margins if the company sustains this trend.
Negative Factors
Weak Cash Generation
Persistent negative operating and free cash flows force reliance on external financing or balance sheet reserves. This structural cash shortfall limits reinvestment, increases dilution or financing risk, and must be remedied for durable independence and to avoid recurring funding events.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
A pronounced top-line rebound in 2025 and >100% reported revenue growth indicate improving product uptake or contract wins. Durable revenue momentum helps absorb fixed costs, supports scaling, and creates a clearer path to sustainable margins if the company sustains this trend.
Read all positive factors
Oakridge Internatinal Ltd (OAK) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.70M
Dividend YieldN/A
Average Volume (3M)3.77K
Price to Earnings (P/E)2.9
Beta (1Y)0.97
Revenue Growth173.74%
EPS Growth88.86%
CountryAU
Employees1
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding26,997,908
10 Day Avg. Volume0
30 Day Avg. Volume3,774
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.92
Price to Sales (P/S)0.77
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oakridge Internatinal Ltd Business Overview & Revenue Model
Company Description
Oakridge International Limited develops Internet of Things technology solutions for consumer, commercial, industrial, and healthcare markets. The company offers DiscoverBus wireless sensor network designed to create secure indoor wireless networks...
Oakridge Internatinal Ltd Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.97M | 2.23M | 814.73K | 1.10M | 496.86K | 908.95K |
| Gross Profit | 936.82K | 1.12M | 481.73K | 89.00K | -253.40K | 64.50K |
| EBITDA | -30.32K | -85.26K | -789.23K | -203.66K | -588.36K | 651.44K |
| Net Income | 170.41K | -128.79K | -761.25K | -116.11K | -531.03K | 603.22K |
Balance Sheet | ||||||
| Total Assets | 2.11M | 1.61M | 1.81M | 1.99M | 2.16M | 2.82M |
| Cash, Cash Equivalents and Short-Term Investments | 213.17K | 530.89K | 1.03M | 1.14M | 1.83M | 2.48M |
| Total Debt | 162.84K | 201.94K | 301.05K | 288.77K | 277.32K | 485.00K |
| Total Liabilities | 1.04M | 703.85K | 776.75K | 755.20K | 810.53K | 863.95K |
| Stockholders Equity | 1.07M | 902.25K | 1.03M | 1.23M | 1.35M | 1.96M |
Cash Flow | ||||||
| Free Cash Flow | -316.10K | -395.68K | -547.36K | -443.06K | -632.93K | 423.19K |
| Operating Cash Flow | -286.76K | -358.46K | -530.67K | -414.60K | -630.80K | 423.59K |
| Investing Cash Flow | -31.48K | -35.07K | -16.68K | 23.19K | -499.00 | 12.07K |
| Financing Cash Flow | 112.35K | -99.11K | 417.03K | -241.96K | -21.18K | 1.57M |
Oakridge Internatinal Ltd Technical Analysis
Negative
0.08
Price Trends
0.08
Negative
0.08
Negative
0.08
Negative
Market Momentum
>-0.01
Positive
17.26
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OAK, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 17.26 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:OAK.
Oakridge Internatinal Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$19.56M | 3.95 | 7.57% | ― | 28.91% | -1050.00% | |
46 Neutral | AU$1.70M | 2.94 | 17.24% | ― | 173.74% | 88.86% | |
43 Neutral | AU$29.84M | -4.21 | -52.26% | ― | -36.68% | 79.41% | |
42 Neutral | AU$9.33M | -2.48 | -578.72% | ― | 241.34% | 44.19% | |
41 Neutral | AU$3.94M | -1.98 | 20.02% | ― | -9.90% | 34.07% | |
41 Neutral | AU$10.13M | -0.96 | 152.58% | ― | -40.05% | -49.57% |
* Healthcare Sector Average
AU:OAK
Oakridge Internatinal Ltd
0.06
>-0.01
-4.55%
AU:RHT
Resonance Health Ltd
0.04
0.00
0.00%
AU:GLH
Global Health Limited
0.07
-0.04
-39.09%
AU:EMD
Emyria Ltd
0.04
<0.01
19.35%
AU:HIQ
HitIQ Limited
0.02
-0.02
-56.76%
AU:ICR
InteliCare Holdings Limited
0.02
<0.01
50.00%
Oakridge Internatinal Ltd Corporate Events
Oakridge International Swings to Profit on 62% Revenue Surge
Feb 11, 2026
Oakridge International Limited reported a strong turnaround in its half-year results to 31 December 2025, with revenue from ordinary activities rising 61.9% to $1.79 million and profit after tax swinging from a loss of $126,968 to a profit of $172...
Oakridge International Posts Solid Quarter as Healthcare Tech Pipeline and RTLS Rollout Advance
Jan 30, 2026
Oakridge International reported a solid December 2025 quarter, driven by growing healthcare technology revenues, stronger customer orders and disciplined cost control, with A$619,000 in customer receipts for the period and A$1.204 million for the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.